1. Dollinger H. C., Raptis S., Grebe B., Goebel H., Müller R., Hinze H. J., Pfeiffer E. F.: The influence of 1-(5-oxohexyl-)3,7-dimethylxanthine (BL 191) on the endocrine and exocrine pancreatic function in man during and following secretin and cholecystokinin-pancreozymin stimulation — Res. exp. Med. (Berl.)161, 327, 1973.
2. Grebe B., Raptis S., Chrissiku M., Müller R., Pfeiffer E. F.: The influence of dime-thylxanthine (BL 191) on the insulin secretion induced by tolbutamide (T), glibenclamide (GL) and glucose (G) in man — Excerpta med. (Amst.)280, 34, 1973.
3. Lehrach F., Müller R.: Ergebnisse der klinischen Prüfung des Vasotherapeutikums 3,7-Dimethyl-1-(5-oxo-hexyl)-xanthin (BL 191) — Arzneimittel-Forsch.21, 1171, 1971.
4. Lenti G., Pagano G., Angotzi G., Basetti-Sani A., Diana A.: Effects of a xanthine derivate (BL 191) on insulin secretion in normal man — Europ. J. clin. Pharmacol.9, 189, 1975.
5. Melani F.: Die radioimmunologische Bestimmung des Insulins — In:Pfeiffer E. F. (Ed.): Handbuch des Diabetes mellitus. Lehmanns, München, 1971; vol. II, p. 69.